Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.eng.2020.06.011 http://scihub22266oqcxt.onion/10.1016/j.eng.2020.06.011 C7332434!7332434!32837750     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Engineering+(Beijing) 2020 ; 6 (10): 1199-204 Nephropedia Template TP {{tp|p=32837750|t=2020. The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol |pdf=|usr=}}{{32837750}} gab.com Text The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol JO: Engineering (Beijing) http://www.kidney.de/pget.php?&tw=1&pmid=32837750 #FOAvip The coronavirus disease 2019 (COVID-19), a pneumonia caused by a novel coronavirus, was reported in December 2019. COVID-19 is highly contagious and has rapidly developed from a regional epidemic into a global pandemic. As yet, no effective drugs have been found to treat this virus. This study, an ongoing multicenter and blind randomized controlled trial (RCT), is being conducted at ten study sites in Heilongjiang Province, China, to investigate the efficacy and safety of Triazavirin (TZV) versus its placebo in COVID-19 patients. A total of 240 participants with COVID-19 are scheduled to be enrolled in this trial. Participants with positive tests of throat swab virus nucleic acid are randomized (1:1) into two groups: standard therapy plus TZV or standard therapy plus placebo for a 7-day treatment with a 21-day follow-up. The primary outcome is the time to clinical improvement of the subjects. Secondary outcomes include clinical improvement rate, time to alleviation of fever, mean time and proportion of obvious inflammatory absorption in the lung, conversion rate of repeated negative virus nucleic acid tests, mortality rate, and conversion rate to severe and critically severe patients. Adverse events, serious adverse events, liver function, kidney function, and concurrent treatments will be monitored and recorded throughout the trial. The results of this trial should provide evidence-based recommendations to clinicians for the treatment of COVID-19. Twit Text FOAVip The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol ????Engineering (Beijing) http://www.kidney.de/pget.php?&tw=1&pmid=32837750 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32837750 #FOAvip English Wikipedia <ref>{{Cite pmid|32837750}}</ref> The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol #MMPMID32837750 Wu X; Yu K; Wang Y; Xu W; Ma H; Hou Y; Li Y; Cai B; Zhu L; Zhang M; Hu X; Gao J; Wang Y; Qin H; Zhao M; Zhang Y; Li K; Du Z; Yang B Engineering (Beijing) 2020[Oct]; 6 (10): 1199-204 PMID32837750show ga The coronavirus disease 2019 (COVID-19), a pneumonia caused by a novel coronavirus, was reported in December 2019. COVID-19 is highly contagious and has rapidly developed from a regional epidemic into a global pandemic. As yet, no effective drugs have been found to treat this virus. This study, an ongoing multicenter and blind randomized controlled trial (RCT), is being conducted at ten study sites in Heilongjiang Province, China, to investigate the efficacy and safety of Triazavirin (TZV) versus its placebo in COVID-19 patients. A total of 240 participants with COVID-19 are scheduled to be enrolled in this trial. Participants with positive tests of throat swab virus nucleic acid are randomized (1:1) into two groups: standard therapy plus TZV or standard therapy plus placebo for a 7-day treatment with a 21-day follow-up. The primary outcome is the time to clinical improvement of the subjects. Secondary outcomes include clinical improvement rate, time to alleviation of fever, mean time and proportion of obvious inflammatory absorption in the lung, conversion rate of repeated negative virus nucleic acid tests, mortality rate, and conversion rate to severe and critically severe patients. Adverse events, serious adverse events, liver function, kidney function, and concurrent treatments will be monitored and recorded throughout the trial. The results of this trial should provide evidence-based recommendations to clinicians for the treatment of COVID-19. äThe Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol (epmc).pdf DeepDyve Pubget Overpricing